Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.66 |
| ▸ | PDE4A | P27815 | 12/20 | 0.66 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544198 | 0.84 | PDE4B (0.71) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL5794099 | 0.82 | PDE4D (0.65) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL18095182 | 0.79 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 0.79 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL30084829 | 0.79 | PDE4B (0.92) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL19158 | 0.79 | PDE4B (1.00) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.79 | PDE4B (0.92) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL5796349 | 0.79 | PDE4B (0.69) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL4429839 | 0.79 | PDE4B (0.45) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.78 | PDE4B (0.98) | PDE4DPDE4BPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213658-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND PROCESS FOR PREPARATION THEREOF | HETERO RESEARCH FOUNDATION | 2016-07-28 | — | — | US | disclosed |
| EP-3043798-A2 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND PROCESS FOR PREPARATION THEREOF | Hetero Research Foundation (IN) | 2016-07-20 | — | — | EP | disclosed |
| US-8034782-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100093635-A1 | Agonists of Guanylate Cyclase UseFul For The Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1536794-A2 | TREATMENT OF RHEUMATOID ARTHRITIS BY INHIBITION OF PDE4 | Merck & Co., Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050014762-A1 | Combination | NYCOMED GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004021987-A2 | TREATMENT OF RHEUMATOID ARTHRITIS BY INHIBITION OF PDE4 | MERCK & CO., INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | PDE4D 9/4885PDE4B 4/4885PDE4A 3/4885 |
| US-20160213658-A1 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST AND PROCESS FOR PREPARATION THEREOF | CMA1, PLAT, CYP3A5 | PDE4D 108/4885PDE4B 41/4885PDE4A 56/4885 |
| US-20050014762-A1 | Combination | PDE4A, PDE4B, PDE3B | PDE4D 10/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.